An Open Label, Multi-centre, Non-interventional Post-marketing Surveillance (PMS) to Monitor the Safety and Effectiveness of HYCAMTIN Administered in Korean Patients According to the Prescribing Information
Phase of Trial: Phase IV
Latest Information Update: 17 Apr 2015
At a glance
- Drugs Topotecan (Primary)
- Indications Cancer
- Focus Adverse reactions
- Sponsors GlaxoSmithKline
- 14 Apr 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
- 23 Dec 2010 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
- 11 Nov 2010 Planned initiation date changed from 1 Oct 2010 to 1 Nov 2010 as reported by ClinicalTrials.gov.